May 16, 2016 / 2:37 PM / a year ago

Valeant move on heart drug rebates 'small step'-top U.S. House Democrat

WASHINGTON, May 16 (Reuters) - Valeant Pharmaceuticals International Inc’s decision to lower costs for two of its heart drugs is a small positive step but does not address high prices for its other products, the top Democrat on the U.S. House of Representatives’ oversight panel said on Monday.

“This is a small step in the right direction, but it comes nowhere close to fully addressing this critical problem,” Representative Elijah Cummings said in a statement, adding that “Valeant also made no mention of its massive price increases on other drugs.” (Reporting by Susan Heavey; Editing by Jeffrey Benkoe)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below